Navigation Links
EndoChoice Announces Health Canada License for Fuse Endoscopy System in Canada
Date:1/14/2014

ATLANTA, Jan. 14, 2014 /PRNewswire/ -- EndoChoice® today announced the company has received a license from Health Canada to market its innovative Fuse™ Full Spectrum Endoscopy™ system in Canada.  The Health Canada license means Fuse will be the first endoscopy system available with expanded viewing capabilities to reach Canadian patients. Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients.

(Photo: http://photos.prnewswire.com/prnh/20140114/CL44806

The Fuse endoscopy system is comprised of colonoscopes and gastroscopes with multiple imagers enabling doctors to see more of the GI tract for diagnosis and treatment. Standard, forward-viewing endoscopy systems have a single imager so clinicians are switching to the Fuse system in an effort to improve the quality of their procedures.

Caption:  The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from standard endoscopes.  In clinical studies, the Fuse system identified 70% more polyps than traditional colonoscopies.  Being able to see more anatomy may allow doctors to find more pre-cancerous polyps like the one in the right screen of this image.

The news from Health Canada enables EndoChoice to begin delivering Fuse endoscopy systems to their gastroenterology specialist customers throughout Canada.

"We intend to gain market clearance in several more countries in the near future," said Mark Gilreath, Founder and CEO at EndoChoice®.  "While 2013 has been an exciting year for our company, the introduction of Fuse into Canada and other markets will enable us to make 2014 even more dynamic as we bring this game-changing technology to more clinicians."

About EndoChoice

Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases.  EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide.  The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine.  To learn more, visit www.endochoice.com

EndoChoice® and Fuse™ are trademarks of EndoChoice®, Inc.

For more information, press only:
Doug Ladd, Chief Marketing Officer
513-608-6873 or Doug.Ladd@endochoice.com


'/>"/>
SOURCE EndoChoice
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EndoChoice Adds Board Members
2. EndoChoice Announces Investigator-Initiated Study Program for Fuse Endoscopy System
3. Full Spectrum Endoscopy from EndoChoice Featured in Live Procedures
4. EndoChoice To Present at J.P. Morgan Healthcare Conference
5. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
6. Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
7. Tekni-Plex, Inc. Announces Expiration Of Change Of Control Offer To Purchase Its 9.750% Senior Secured Notes Due 2019
8. Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
9. Adaptive Announces a Biomarker Discovery Agreement with Johnson & Johnson Innovation
10. Medical Tracking Solutions, Inc. announces new client NovaBone Products, LLC
11. Volcano Corporation Announces Preliminary Fourth Quarter 2013 Revenues; Year-Over-Year Annual Revenues Increase Eight Percent On A Constant Currency Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):